Biomedical Engineering Reference
In-Depth Information
183. Nakagawa, R, Hara, Y, Arakawa, H, Nishimura, S, and Komatani, H. 2002. ABCG2
confers resistance to indolocarbazole compounds by ATP-dependent transport. Biochem
Biophys Res Commun 299:669-675.
184. Chen, ZS, Robey, RW, Belinsky, MG, Shchaveleva, I, Ren, XQ, Sugimoto, Y, Ross, DD,
Bates, SE, and Kruh, GD. 2003. Transport of methotrexate, methotrexate polyglutamates,
and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations
at R482 on methotrexate transport. Cancer Res 63:4048-4054.
185. Volk, EL, and Schneider, E. 2003. Wild-type breast cancer resistance protein
(BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res 63:5538-
5543.
186. Shafran, A, Ifergan, I, Bram, E, Jansen, G, Kathmann, I, Peters, GJ, Robey, RW, Bates,
SE, and Assaraf, YG. 2005. ABCG2 harboring the Gly482 mutation confers high-level
resistance to various hydrophilic antifolates. Cancer Res 65:8414-22.
187. Mitomo, H, Kato, R, Ito, A, Kasamatsu, S, Ikegami, Y, Kii, I, Kudo, A, Kobatake, E,
Sumino, Y, and Ishikawa, T. 2003. A functional study on polymorphism of the ATP-
binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate trans-
port. Biochem J 373:767-774.
188. Wang, X, Nitanda, T, Shi, M, Okamoto, M, Furukawa, T, Sugimoto, Y, Akiyama, S,
and Baba, M. 2004. Induction of cellular resistance to nucleoside reverse transcriptase
inhibitors by the wild-type breast cancer resistance protein. Biochem Pharmacol 68:1363-
1370.
189. Scharenberg, CW, Harkey, MA, and Torok-Storb, B. 2002. The ABCG2 transporter is an
efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human
hematopoietic progenitors. Blood 99:507-512.
190. Youdim, KA, Qaiser, MZ, Begley, DJ, Rice-Evans, CA, and Abbott, NJ. 2004. Flavonoid
permeability across an in situ model of the blood-brain barrier. Free Radic Biol Med
36:592-604.
191. Ebert, B, Seidel, A, and Lampen, A. 2005. Identification of BCRP as transporter of
benzo[a]pyrene conjugates metabolically formed in Caco-2 cells and its induction by
Ah-receptor agonists. Carcinogenesis 26:1754-1763.
192. Mizuno, N, Suzuki, M, Kusuhara, H, Suzuki, H, Takeuchi, K, Niwa, T, Jonker,
JW, and Sugiyama, Y. 2004. Impaired renal excretion of 6-hydroxy-5,7-dimethyl-
2-methylamino-4-(3-pyridylmethyl) benzothiazole (E3040) sulfate in breast cancer
resistance protein (BCRP1/ABCG2) knockout mice. Drug Metab Dispos 32:898-
901.
193. Lee, YJ, Kusuhara, H, Jonker, JW, Schinkel, AH, and Sugiyama, Y. 2005. Investigation of
efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-
brain barrier: a minor role of breast cancer resistance protein. J Pharmacol Exp Ther
312:44-52.
194. Zamek-Gliszczynski, MJ, Hoffmaster, KA, Tian, X, Zhao, R, Polli, JW, Humphreys, JE,
Webster, LO, Bridges, AS, Kalvass, JC, and Brouwer, KL. 2005. Multiple mechanisms
are involved in the biliary excretion of acetaminophen sulfate in the rat: role of Mrp2 and
Bcrp1. Drug Metab Dispos 33:1158-1165.
195. Merino, G, Jonker, JW, Wagenaar, E, Pulido, MM, Molina, AJ, Alvarez, AI, and Schinkel,
AH. 2005. Transport of anthelmintic benzimidazole drugs by breast cancer resistance
protein (BCRP/ABCG2). Drug Metab Dispos 33:614-618.
Search WWH ::
Custom Search